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Abstract
Objective: We reported a rare case of intracranial localized sarcoidosis.
Case presentation: A 48-year-old woman suffered from right hemiparesis. The symptoms gradually got 
worse after the onset and she was admitted into our hospital. A plain computed tomography (CT) revealed 
an isodensity mass with perifocal edema in the left frontal lobe. Gadolinium-enhanced magnetic resonance 
imaging (MRI) showed a well-enhanced mass accompanied by dural tail signs in the same place. The 
enhanced mass was irregular and arborescent in shape and extended along the sulci. The open biopsy was 
performed and the frozen section suggested sarcoidosis involving the dura mater. A part of the lesion was 
removed and was histologically diagnosed as sarcoidosis. A gadolinium-enhanced MRI was performed to 
evaluate post-operative state at the next day and showed that about half of the mass lesion was removed. 
The gadolinium-enhanced MRI, however, showed that the mass of the lesion had increased in volume 
and had reached to the preoperative size 13 days after operation. Symptoms improved and radiological 
findings became unclear due to oral steroid therapy until three months after discharge. Perifocal edema 
and enhancement effected by the mass also disappeared. MRI showed that other new lesions appeared in 
regions of the brain other than the primary lesion one and a half years after surgery, and the oral steroid 
therapy was continuously given.
Conclusion: Removal of the lesion of localized neuro-sarcoidosis was not effective for mass reduction, but 
oral steroid therapy was effective. The open biopsy was necessary to make an early and exact diagnosis of 
sarcoidosis, because long-term and mass administration of the steroid may be needed for the sarcoidosis, 
and it may help to reduce severe side effects of steroid therapy.
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Ⅱ .   症　例 
症　例：48 歳，女性
主　訴：右上下肢脱力
既往歴：帝王切開 , 喘息 , 右尿管結石 , 右鼻涙
管閉塞症 , 心室性期外収縮














図１：Computed tomography image shows a mass 
lesion with perifocal edema in the left frontal 
lobe.
図２：Preoperative gadolinium-enhanced T1-weighted 
MR images in the sagittal (a), coronal(b) and 
axial(c,d) section reveal a homogeneously 
enhanced mass lesion  in the left frontal region. 
T2–weighted axial MRI(e) shows hyperintense 
lesions in precentral gyrus and superior frontal 
gyrus.
11症例：中枢神経系限局性神経サルコイドーシスの 1 例
左前頭葉の iso. ～ hypodensity な mass lesion
を周囲脳浮腫と考えられる low density area が
囲んでいた．頭部造影 MRI T1 強調画像では，
左前頭葉の上前頭回から中心前回を中心に，脳
溝に沿って樹枝状に拡がり異常濃染される 27
× 26mm の mass と dural tail sign を認めた（図
2a,b,c,d）．この mass は拡散強調画像で軽度高
信号を呈し，T2強調画像ではこのmass周囲の，
脳浮腫と考えられる high intensity area が強調
されていた（図 2e）．
血清学的精査 ( 入院時 )：CRP；0.43 mg/dl, 
Ca；8.2 mg/dl, PTH；50 pg/ml, RF；6 IU/
ml, ACE；16.6 U/l, IgA；167 mg/dl, IgG1；
586 mg/dl, IgG2；347 mg/dl, IgG3；42.1 mg/
dl, IgG4；8.0 mg/dl, PR3-ANCA；＜ 1.0 U/ml, 










































図３：Intraoperative fi ndings reveal subdural granular 
lesions(a)　and thickening of the arachnoid 










図５：Gadolinium-enhanced T1-weighted MR images 
of one day(a,b,c) and thirteen days(e,f,g) after 
operation. The remaining mass lesions increase 
in volume in Fig. e, f and g.
図６：Gadol in ium-enhanced T1-weighted MR 
images after discharge. Axial section shows 
homogeneously enhanced mass lesions at 
the anterior nucleus of the right thalamus 
which newly appeared after discharge. It was 
recognized that sarcoidosis might disseminate in 
the brain or appear as de novo lesion (a). The 
recurrence or re-growing of sarcoidosis did not 
recognized in the left frontal lobe (b).
図４b：
Microscopic findings revealed non-caseating 
epithelioid cell granulomas involving the brain tissue. 














た（図 5a,b,c）．術後，デカドロン 2 mg/day で
内服治療を開始し，10 日間で漸減中止した．
術後 13 日目 頭部 MRI（図 5d,e,f）では摘出腔に，
摘出前と同様の大きさまで腫瘤が再増大し，周
囲脳浮腫の範囲も増大していた．デカドロン内









が，退院 1 年後の頭部 MRI( 図 6) で，右視床
前核に 5 mm 径の腫瘤性病変を認め，サルコ
イドーシスが再発した可能性が示唆され，治療
が継続された．



































































40 mg/day から開始し，漸減して 6 か月後に
は 15 ～ 20 mg/day まで減量．さらに 2 年程継
続し症状が安定した後に，5 mg/year ずつ減量





































































































に対する MTX の使用について，米国の 2 年以
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